|
FBXO30 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.23999740767545E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.30589983271534E-10 |
| Normal-vs-Stage2 |
1.64950053616053E-10 |
| Normal-vs-Stage3 |
4.16100487399262E-11 |
| Normal-vs-Stage4 |
4.07684996872604E-12 |
| Stage1-vs-Stage2 |
9.240600E-01 |
| Stage1-vs-Stage3 |
3.253000E-01 |
| Stage1-vs-Stage4 |
1.085660E-02 |
| Stage2-vs-Stage3 |
4.784000E-01 |
| Stage2-vs-Stage4 |
5.174300E-02 |
| Stage3-vs-Stage4 |
2.302600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.80849796144389E-11 |
| Normal-vs-AfricanAmerican |
1.13450000505111E-08 |
| Normal-vs-Asian |
1.30619959293199E-11 |
| Caucasian-vs-AfricanAmerican |
2.140600E-01 |
| Caucasian-vs-Asian |
4.376200E-01 |
| AfricanAmerican-vs-Asian |
1.497600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.22609766362825E-11 |
| Normal-vs-Female |
5.7697957522862E-11 |
| Male-vs-Female |
8.097600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.37890032725352E-10 |
| Normal-vs-Age(41-60Yrs) |
7.29519777920018E-11 |
| Normal-vs-Age(61-80Yrs) |
2.10389483612516E-11 |
| Normal-vs-Age(81-100Yrs) |
1.19750000027175E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.488800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.532590E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.562600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.248600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.762000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.767600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.021130E-04 |
| Classical-VS-Follicular |
2.109700E-02 |
| Classical-VS-Other |
9.977000E-01 |
| Classical-VS-Normal |
8.65609806055545E-11 |
| Tall-VS-Follicular |
2.9043000000506E-06 |
| Tall-VS-Other |
4.081900E-02 |
| Tall-VS-Normal |
2.39652742095586E-12 |
| Follicular-VS-Other |
1.682370E-01 |
| Follicular-VS-Normal |
8.58659998659306E-09 |
| Other-VS-Normal |
3.54999996066141E-09 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.25759958002902E-10 |
| Normal-vs-N1 |
2.83109979903884E-10 |
| N0-vs-N1 |
6.102400E-01 |
|
|
